Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury

Jakob Vinten-Johansen, Rong Jiang, James G. Reeves, James Mykytenko, Jeremiah Deneve, Lynetta Johnson Jobe

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Ischemic myocardium must be reperfused to terminate the ischemic event; otherwise the entire myocardium involved in the area at risk will not survive. However, there is a cost to reperfusion that may offset the intended clinical benefits of minimizing infarct size, postischemic endothelial and microvascular damage, blood flow defects, and contractile dysfunction. There are many contributors to this reperfusion injury. Targeting only one factor in the complex web of reperfusion injury is not effective because the untargeted mechanisms induce injury. An integrated strategy of reducing reperfusion injury in the catheterization laboratory involves controlling both the conditions and the composition of the reperfusate. Mechanical interventions such as gradually restoring blood flow or applying postconditioning may be used independently in or conjunction with various cardioprotective pharmaceuticals in an integrated strategy of reperfusion therapeutics to reduce postischemic injury.

Original languageEnglish (US)
Pages (from-to)123-145
Number of pages23
JournalHematology/Oncology Clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Myocardial Reperfusion Injury
Inflammation Mediators
Reperfusion Injury
Myocardial Ischemia
Reperfusion
Myocardium
Wounds and Injuries
Catheterization
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Vinten-Johansen, J., Jiang, R., Reeves, J. G., Mykytenko, J., Deneve, J., & Jobe, L. J. (2007). Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury. Hematology/Oncology Clinics of North America, 21(1), 123-145. https://doi.org/10.1016/j.hoc.2006.11.010

Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury. / Vinten-Johansen, Jakob; Jiang, Rong; Reeves, James G.; Mykytenko, James; Deneve, Jeremiah; Jobe, Lynetta Johnson.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 1, 01.02.2007, p. 123-145.

Research output: Contribution to journalReview article

Vinten-Johansen, J, Jiang, R, Reeves, JG, Mykytenko, J, Deneve, J & Jobe, LJ 2007, 'Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury', Hematology/Oncology Clinics of North America, vol. 21, no. 1, pp. 123-145. https://doi.org/10.1016/j.hoc.2006.11.010
Vinten-Johansen, Jakob ; Jiang, Rong ; Reeves, James G. ; Mykytenko, James ; Deneve, Jeremiah ; Jobe, Lynetta Johnson. / Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury. In: Hematology/Oncology Clinics of North America. 2007 ; Vol. 21, No. 1. pp. 123-145.
@article{3ca7324333b04f7a99ae80a769490a1e,
title = "Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury",
abstract = "Ischemic myocardium must be reperfused to terminate the ischemic event; otherwise the entire myocardium involved in the area at risk will not survive. However, there is a cost to reperfusion that may offset the intended clinical benefits of minimizing infarct size, postischemic endothelial and microvascular damage, blood flow defects, and contractile dysfunction. There are many contributors to this reperfusion injury. Targeting only one factor in the complex web of reperfusion injury is not effective because the untargeted mechanisms induce injury. An integrated strategy of reducing reperfusion injury in the catheterization laboratory involves controlling both the conditions and the composition of the reperfusate. Mechanical interventions such as gradually restoring blood flow or applying postconditioning may be used independently in or conjunction with various cardioprotective pharmaceuticals in an integrated strategy of reperfusion therapeutics to reduce postischemic injury.",
author = "Jakob Vinten-Johansen and Rong Jiang and Reeves, {James G.} and James Mykytenko and Jeremiah Deneve and Jobe, {Lynetta Johnson}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.hoc.2006.11.010",
language = "English (US)",
volume = "21",
pages = "123--145",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Inflammation, Proinflammatory Mediators and Myocardial Ischemia-reperfusion Injury

AU - Vinten-Johansen, Jakob

AU - Jiang, Rong

AU - Reeves, James G.

AU - Mykytenko, James

AU - Deneve, Jeremiah

AU - Jobe, Lynetta Johnson

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Ischemic myocardium must be reperfused to terminate the ischemic event; otherwise the entire myocardium involved in the area at risk will not survive. However, there is a cost to reperfusion that may offset the intended clinical benefits of minimizing infarct size, postischemic endothelial and microvascular damage, blood flow defects, and contractile dysfunction. There are many contributors to this reperfusion injury. Targeting only one factor in the complex web of reperfusion injury is not effective because the untargeted mechanisms induce injury. An integrated strategy of reducing reperfusion injury in the catheterization laboratory involves controlling both the conditions and the composition of the reperfusate. Mechanical interventions such as gradually restoring blood flow or applying postconditioning may be used independently in or conjunction with various cardioprotective pharmaceuticals in an integrated strategy of reperfusion therapeutics to reduce postischemic injury.

AB - Ischemic myocardium must be reperfused to terminate the ischemic event; otherwise the entire myocardium involved in the area at risk will not survive. However, there is a cost to reperfusion that may offset the intended clinical benefits of minimizing infarct size, postischemic endothelial and microvascular damage, blood flow defects, and contractile dysfunction. There are many contributors to this reperfusion injury. Targeting only one factor in the complex web of reperfusion injury is not effective because the untargeted mechanisms induce injury. An integrated strategy of reducing reperfusion injury in the catheterization laboratory involves controlling both the conditions and the composition of the reperfusate. Mechanical interventions such as gradually restoring blood flow or applying postconditioning may be used independently in or conjunction with various cardioprotective pharmaceuticals in an integrated strategy of reperfusion therapeutics to reduce postischemic injury.

UR - http://www.scopus.com/inward/record.url?scp=33846506801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846506801&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2006.11.010

DO - 10.1016/j.hoc.2006.11.010

M3 - Review article

C2 - 17258123

AN - SCOPUS:33846506801

VL - 21

SP - 123

EP - 145

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -